Another company, Seraxis, has plans to employ their hPSC-derived insulin-secreting cells along with encapsulation system SeraGraft, for T1D clinical trial (https://www.seraxis.com/seraxis-technology/). Here, INS is linked to type 1 diabetes mellitus.